Nectar Lifesciences Limited has announced that its board meeting is scheduled to take place on Saturday, May 30, 2026. The meeting will be held to consider and approve the audited financial results for the financial year 2025-26. The board will also deliberate on the financial statements of the company for the said financial year and matters related thereto.

The intimation was sent to the National Stock Exchange of India Limited and BSE Limited on May 25, 2026. The notice references Regulation 29, 30, 33 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Meeting Details

The following table summarizes the key details regarding the upcoming board meeting:

The board's decision on the financial results and statements will be disclosed following the conclusion of the meeting.

Nectar lifesciences Limited has successfully concluded its income tax assessment litigation with a favorable order from the Deputy Commissioner of Income Tax (DCIT), Chandigarh. The pharmaceutical company announced that the DCIT disposed of the assessment matter for Assessment Year 2017-18 in the company's favor through an order dated March 31, 2026.

Case Background and Timeline

The litigation originated when Nectar Lifesciences challenged notices issued under Sections 148 and 148A(b) of the Income Tax Act, 1961, covering Assessment Years 2017-18 to 2021-22. The company filed a writ petition before the Punjab and Haryana High Court, which directed the Income Tax Department to dispose of the company's objections within eight weeks.

Recent Development Details

The Deputy Commissioner of Income Tax, Central Circle-1, Chandigarh, issued the favorable order for Assessment Year 2017-18 on March 31, 2026. The company received this order via email on April 9, 2026. According to the company's disclosure, this order has no expected financial implications, with the quantum of claims listed as NIL.

Financial Impact and Conclusion

The favorable resolution carries no financial burden for Nectar Lifesciences. The company confirmed that with this latest order, the entire matter stands fully concluded across all contested assessment years.

Disclosure Timeline

The company acknowledged a delay in providing these details to the stock exchanges, attributing it to temporary inaccessibility of a registered email ID of a former employee who had left the organization. Nectar Lifesciences expressed regret for the omission and assured the exchanges of its commitment to furnishing all material information within prescribed time limits in the future.

This successful resolution of the income tax assessment matter removes a potential regulatory overhang for the pharmaceutical company, allowing it to focus on its core business operations without the burden of ongoing tax litigation.